Lupin on Thursday said it has received final approval from the US health regulator to market its Clonidine Hydrochloride extended release tablets used for treatment of attention deficit hyperactivity disorder. The company has received USFDA’s final approval to market the tablets in the strength of 0.1 mg, Lupin said in a notice to the stock exchanges. Shares of Lupin will remain in focus, as investors are likely to closely watch the development.